Last week our team unveiled the Nio™+ physically at Oxford Global's NextGen Omics conference in London, UK.
A booth packed with curious people, and a feedback from our early access users at CHU de Rennes.
Couldn't attend live? Watch on-demand here https://t.co/p3kXhLEEJc
Next to experts in oncology & digital PCR, our team also gave early access to the team at Exothera.
Learn how they experienced our next product on November 10th, register via https://t.co/2L3QPJZbd6
700+ people have registered for us taking the next leap forward in digital PCR. Spanning well over 40 different nationalities across the globe.
Do not miss out & register for our product announcement below:
https://t.co/SSMqNEmwbN
We're collaborating with Europe's leading digital PCR innovators. These past weeks we've collaborated with digital PCR consortium at the University of Ghent.
Curious to learn more? Hear all about it during our November 10th announcement
https://t.co/c5rdolA4rr
During our early access programme, we're working with leading institutes in oncology, cell and gene therapy as well as digital PCR technology experts.
Last week: Centre Eugène Marquis in Rennes, France.
Learn about it during our Nov. 10th announcement:
https://t.co/sVvOxz4Ner
Great @biocompare piece on the best uses for dPCR and qPCR. Stilla’s Matthew Grow discusses multiplexed dPCR as a diagnostic complementary to NGS that can allow hospital labs to run more in-house patient testing in place of outsourced or centralized labs: https://t.co/bojAVjMLuv
For our second installment of #StillaSpotlight, meet Kimberley Gutierrez, PhD, Business Development, Applications Lead. Kim has her sights set on the future of PCR and is excited to see digital PCR grow more in the clinical market and become a new gold standard.
We had a fantastic time at today’s Genomics in Precision Oncology Xchange, where Stilla’s co-founder and Dir. of Business & Corp. Development Clément Gay gave the keynote: “Getting de-centralized testing into routine clinical oncology using high-performance genetic multiplexing.”
Join us & others at our European Genomics in Precision Oncology hybrid roundtable Xchange in Munich, June 28. View agenda & register at https://t.co/jV4uy4pNXv. Open to Senior Scientists in the pharma/biotech industry #Oncology#Genomics#lifesciences#pharmacology#Biotechnology
Are you familiar with Limit of Blank (LoB) and Limit of Detection (LoD)? Determining a false-positive cutoff when quantifying nucleic acids is critical to the robustness and reliability of a dPCR assay. Check out our technical note: https://t.co/7CVId0LqHx
We’re feeling inspired after participating in the Bioserra LabCluster Tour with other innovative companies including our partner @promega. The Stilla team presented on high-multiplexing #digitalPCR tech in oncology—from clinical research to drug development to patient follow-up.